Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Diseases of the Esophagus

Neoadjuvant Chemoimmunotherapy With Adaptive Radiotherapy for Esophageal Squamous Cell Carcinoma: Study Protocol for a Prospective Multicenter Phase Ii Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

WJWei JiangKXKunpeng XuSCSonghua Cai

Discussion

Loading...

Member takes

Overview

Prospective multicenter phase II trial aims to enhance pathologic complete response in esophageal cancer, indicating adaptive treatment may reduce toxicity.

Key Points

  • The trial aims to explore a new adaptive protocol that improves pathologic complete response in esophageal squamous cell carcinoma.
  • Approximately 61 patients will initiate therapy with low-dose radiotherapy and chemoimmunotherapy, anticipating a notable change in treatment outcomes.
  • This is a prospective multicenter phase II trial utilizing an adaptive enrichment design to refine treatment based on tumor response.
  • By focusing treatment intensity on tumor response, this approach may redefine neoadjuvant therapy and improve patient survival rates.

Cite This Study

Jiang et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478b8d6https://doi.org/10.1093/dote/doaf061.120
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1107. CAMRELIZUMAB AND LOW-DOSE RADIOTHERAPY WITH CONCURRENT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (NICE-RT STUDY): PRELIMINARY RESULTS2025
  2. 2474. NEOADJUVANT CHEMOIMMUNOTHERAPY VERSUS CHEMOTHERAPY PLUS ESOPHAGECTOMY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: PRIMARY RESULT OF A RANDOMIZED CLINICAL TRIAL2025
  3. 3236. SAFETY AND EFFICACY OF CAMRELIZUMAB COMBINED WITH RADIOTHERAPY AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025
  4. 4135. COMPARISON BETWEEN NEOADJUVANT-CHEMORADIOTHERAPY FOLLOWED BY SURGERY AND DEFINITIVE CHEMORADIOTHERAPY FOR SURVIVAL IN PATIENTS WITH RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA (JCOG2305A)2025
  5. 5207. LOW-DOSE INVOLVED-FIELD RT, PLUS IMMUNOCHEMOTHERAPY SHOWED EXCELLENT EFFICACY AND LOW TOXICITIES IN UNRESECTABLE LA-ESCC: A PROSPECTIVE PHASE II STUDY2025